128 related articles for article (PubMed ID: 38265945)
1. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort.
Elhai M; Sritharan N; Boubaya M; Balbir-Gurman A; Siegert E; Hachulla E; de Vries-Bouwstra J; Riemekasten G; Distler JHW; Rosato E; Del Galdo F; Mendoza FA; Furst DE; de la Puente C; Hoffmann-Vold AM; Gabrielli A; Distler O; Bloch-Queyrat C; Allanore Y;
Lancet Rheumatol; 2022 Nov; 4(11):e785-e794. PubMed ID: 38265945
[TBL] [Abstract][Full Text] [Related]
2. Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts.
Liem SIE; Boonstra M; le Cessie S; Riccardi A; Airo P; Distler O; Matucci-Cerinic M; Caimmi C; Siegert E; Allanore Y; Huizinga TWJ; Toes REM; Scherer HU; de Vries-Bouwstra JK;
Lancet Rheumatol; 2022 Oct; 4(10):e699-e709. PubMed ID: 38265968
[TBL] [Abstract][Full Text] [Related]
3. Do We Have Good Activity Indices in Systemic Sclerosis?
Groseanu L; Petrescu S; Balanescu A; Bojinca V; Opris-Belinski D; Berghea F; Mazilu D; Saulescu I; Borangiu A; Daia-Iliescu S; Constantinescu C; Cobilinschi C; Abobului M; Negru MM; Ionescu R
Curr Rheumatol Rev; 2022; 18(1):39-47. PubMed ID: 34517805
[TBL] [Abstract][Full Text] [Related]
4. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
[TBL] [Abstract][Full Text] [Related]
5. Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis.
Sobanski V; Giovannelli J; Allanore Y; Riemekasten G; Airò P; Vettori S; Cozzi F; Distler O; Matucci-Cerinic M; Denton C; Launay D; Hachulla E;
Arthritis Rheumatol; 2019 Sep; 71(9):1553-1570. PubMed ID: 30969034
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.
Ferreli C; Gasparini G; Parodi A; Cozzani E; Rongioletti F; Atzori L
Clin Rev Allergy Immunol; 2017 Dec; 53(3):306-336. PubMed ID: 28712039
[TBL] [Abstract][Full Text] [Related]
7. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
[TBL] [Abstract][Full Text] [Related]
8. MRI Digital Artery Volume Index (DAVIX) as a surrogate outcome measure of digital ulcer disease in patients with systemic sclerosis: a prospective cohort study.
Hughes M; Di Donato S; Gjeloshi K; Abignano G; Danzo F; Lettieri G; De Lorenzis E; Bertham D; O'Connor P; Kubassova O; Dehmeshki J; Del Galdo F
Lancet Rheumatol; 2023 Oct; 5(10):e611-e621. PubMed ID: 38251485
[TBL] [Abstract][Full Text] [Related]
9. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
Walker UA; Tyndall A; Czirják L; Denton C; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Bocelli-Tyndall C; Matucci-Cerinic M
Ann Rheum Dis; 2007 Jun; 66(6):754-63. PubMed ID: 17234652
[TBL] [Abstract][Full Text] [Related]
10. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database.
Wirz EG; Jaeger VK; Allanore Y; Riemekasten G; Hachulla E; Distler O; Airò P; Carreira PE; Tikly M; Vettori S; Balbir Gurman A; Damjanov N; Müller-Ladner U; Distler J; Li M; Häusermann P; Walker UA;
Ann Rheum Dis; 2016 Jul; 75(7):1285-92. PubMed ID: 26232495
[TBL] [Abstract][Full Text] [Related]
11. A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand.
Chang WS; Schollum J; White DH; Solanki KK
Clin Rheumatol; 2015 Nov; 34(11):1921-7. PubMed ID: 26022620
[TBL] [Abstract][Full Text] [Related]
12. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.
Wu W; Jordan S; Graf N; de Oliveira Pena J; Curram J; Allanore Y; Matucci-Cerinic M; Pope JE; Denton CP; Khanna D; Distler O;
Ann Rheum Dis; 2019 May; 78(5):648-656. PubMed ID: 30852552
[TBL] [Abstract][Full Text] [Related]
13. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study.
Avouac J; Walker UA; Hachulla E; Riemekasten G; Cuomo G; Carreira PE; Caramaschi P; Ananieva LP; Matucci-Cerinic M; Czirjak L; Denton C; Ladner UM; Allanore Y; ;
Ann Rheum Dis; 2016 Jan; 75(1):103-9. PubMed ID: 25165035
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Features, Autoantibody Profile, and Nailfold Capillaroscopy of Systemic Sclerosis: A Study of 60 Cases.
Dave J; Mahajan S; Khadilkar P; Pradhan V
J Assoc Physicians India; 2022 Nov; 70(11):11-12. PubMed ID: 37355940
[TBL] [Abstract][Full Text] [Related]
15. Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening.
Lazzaroni MG; Cavazzana I; Colombo E; Dobrota R; Hernandez J; Hesselstrand R; Varju C; Nagy G; Smith V; Caramaschi P; Riccieri V; Hachulla E; Balbir-Gurman A; Chatelus E; Romanowska-Próchnicka K; Araújo AC; Distler O; Allanore Y; Airò P;
J Rheumatol; 2017 May; 44(5):639-647. PubMed ID: 28089973
[TBL] [Abstract][Full Text] [Related]
16. Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort.
Ciaffi J; Liem SIE; Cannegieter S; Ahmed S; Hoekstra EM; Wiland P; Atsumi T; Szücs G; Balbir Gurman A; Czirják L; Zanatta E; Koetter I; Henes JC; Matucci-Cerinic M; Airò P; Ursini F; Huizinga TWJ; De Vries-Bouwstra J; Collaborators E
RMD Open; 2024 May; 10(2):. PubMed ID: 38772679
[TBL] [Abstract][Full Text] [Related]
17. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients.
Poormoghim H; Lucas M; Fertig N; Medsger TA
Arthritis Rheum; 2000 Feb; 43(2):444-51. PubMed ID: 10693887
[TBL] [Abstract][Full Text] [Related]
18. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.
Becker M; Graf N; Sauter R; Allanore Y; Curram J; Denton CP; Khanna D; Matucci-Cerinic M; de Oliveira Pena J; Pope JE; Distler O; ;
Ann Rheum Dis; 2019 Sep; 78(9):1242-1248. PubMed ID: 31227488
[TBL] [Abstract][Full Text] [Related]
19. Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China.
Hu S; Hou Y; Wang Q; Li M; Xu D; Zeng X
Arthritis Res Ther; 2018 Oct; 20(1):235. PubMed ID: 30348207
[TBL] [Abstract][Full Text] [Related]
20. Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database.
Allanore Y; Bozzi S; Terlinden A; Huscher D; Amand C; Soubrane C; Siegert E; Czirják L; Carreira PE; Hachulla E; Zanatta E; Li M; Airò P; Mendoza FA; Rosato E; Distler O;
Arthritis Res Ther; 2020 Oct; 22(1):257. PubMed ID: 33115544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
